argenx (ARGX) Names Karl Gubitz CFO streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Published: Jun 03, 2021 By Alex Keown
180 Life Sciences Russell T. Ray and Teresa DeLuca were appointed to the board of directors of 180 Life Sciences. Ray was formerly Managing Director and co-Head of Global Health Care at Credit Suisse First Boston Corporation. More recently, Ray was a Partner and Senior Advisor to HLM Venture Partners, a health care-focused venture capital firm. He currently serves on the board of directors of Merrimack Pharmaceuticals, Inc. DeLuca comes to 180 Life Sciences as both a public independent board director and former senior executive Chief Medical Officer. Her most recent role was at Columbia University as Managing Director of NY Life Science Venture Fund.
CureVac Appoints Klaus Edvardsen as Chief Development Officer
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 2, 2021 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ( mRNA ), today announced the appointment of Klaus Edvardsen, MD, PhD, as Chief Development Officer. The appointment of Dr. Edvardsen will take effect on August 1, 2021. We are very happy to welcome Dr. Edvardsen to the CureVac leadership team, said Jean Stéphenne, Chairman of the Supervisory Board of CureVac. He has a tremendous background, having led both business development and clinical research on a global scale for several high-profile biopharmaceutical companies. His great breadth of knowledge and expertise in research and different therapeutic areas will serve CureVac well as it continues to evolve from a research-oriented biotechnology to a fully integrated biopharmaceutical compan